Bluejay Diagnostics Announces Closing of $8.75 Million Underwritten Public Offering

Core Viewpoint - Bluejay Diagnostics, Inc. has successfully closed a public offering, raising approximately $8.75 million in gross proceeds to enhance its medical technology capabilities in rapid diagnostics for critical care settings [3]. Group 1: Offering Details - The offering consisted of 5,368,098 Common Units or Prefunded Units, with each unit priced at $1.63 for Common Units and $1.6299 for Prefunded Units [3]. - Aegis Capital Corp. has been granted a 45-day option to purchase additional shares, representing up to 15% of the securities sold in the offering [2]. - The offering was conducted under a registration statement that became effective on June 26, 2024 [11]. Group 2: Use of Proceeds - The net proceeds from the offering will be used to repay $2.3 million in outstanding debt, fund FDA approval-related activities, and support research and development efforts [10]. Group 3: Company Overview - Bluejay Diagnostics focuses on improving patient outcomes through its Symphony System, which provides rapid testing for sepsis triage and monitoring [5]. - The company's first product candidate, an IL-6 Test for sepsis, aims to deliver results in approximately 20 minutes [5].